Proteome Sciences plc (PRM) Fair Value & Analysis
Healthcare · GB · Market cap 7.0M GBX
Fair value as of: Jul 16, 2026
From 3 valuation models · updated today
Fair value updated Jul 16, 2026, revised from £23.09 to £0.0223 (−99.9%) since Jun 26, 2026. Share price +21.9% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0131 – £0.0369 · fair‑value band £0.0188 – £0.0268 · the £0.0200 price screens below the £0.0223 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Proteome Sciences plc (PRM) currently trades at £0.0200, while our model-based Fair Value estimate is £0.0223, implying the stock looks roughly 11.3% undervalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Proteome Sciences plc generated revenue of £3.8M at a net margin of -81.5%. Revenue declined 28.9% year over year. Net debt stands at £15.0M. Fundamentals as of Jul 16, 2026
Our scenario range runs from £0.0188 (bear case) to £0.0268 (bull case); at £0.0200, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at 11%, PRM screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM); SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Proteome Sciences plc reported revenue of £3.8M in FY2025 versus £5.1M in FY2021, a compound −7.5%/yr. Reported net income was −£3.1M in FY2025.
Is PRM fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DAP | €157.35 | €73.68 | -53% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
| Waters Corporation WAT | $363.18 | $113.71 | -69% |
| Integrated Diagnostics Holdings IDHC | $0.5800 | $1.35 | +133% |
| IQVIA Holdings IQV | $182.17 | $119.25 | -35% |
| Mettler-Toledo International Inc MTD | $1,154 | $547.22 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Proteome Sciences plc (PRM) undervalued?
What is the fair value of PRM?
What is the quality score of PRM?
What is the revenue of Proteome Sciences plc (PRM)?
What is the net profit margin of PRM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Proteome Sciences plc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.